Activation of NRF2 by dexamethasone in ataxia telangiectasia cells involves KEAP1 inhibition but not the inhibition of p38

Sara Biagiotti¹*, Marzia Bianchi¹, Luigia Rossi¹, Luciana Chessa², Mauro Magnani¹

¹ Department of Biomolecular Sciences, University of Urbino, Urbino, Italy, ² Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy

* sara.biagiotti@uniurb.it

Abstract

Oxidative stress has been shown to play a crucial role in the pathophysiology of the neurodegenerative disease Ataxia Telangiectasia. We have recently demonstrated that Dexamethasone treatment is able to counteract the oxidative state by promoting nuclear factor erythroid 2-related factor 2 (NRF2) nuclear accumulation. However, substantial gaps remain in our knowledge of the underlying molecular mechanism(s) according to which Dexamethasone acts as an NRF2 inducer. Herein we investigate the possible effects of the drug on the main NRF2 activation pathways by initially focusing on key kinases known to differently affect NRF2 activation. Neither AKT nor ERK1/2, known to be NRF2-activating kinases, were found to be activated upon Dexamethasone treatment, thus excluding their involvement in the transcription factor nuclear shift. Likewise, GSK3 inactivating kinase was not inhibited, thus ruling out its role in NRF2 activation. On the other hand, p38 MAPK, another NRF2-inhibitory kinase, was indeed switched-off in Ataxia Telangiectasia cells by Dexamethasone-mediated induction of DUSP1 phosphatase, and therefore it appeared that it might account for NRF2 triggering. However, this mechanism was excluded by the use of a selective p38 inhibitor, which failed to cause a significant NRF2 nuclear shift and target gene induction. Finally, dexamethasone effects on the classical oxidative pathway orchestrated by KEAP1 were addressed. Dexamethasone was found to decrease the expression of the inhibitor KEAP1 at both mRNA and protein levels and to induce the shift from the reduced to the oxidized form of KEAP1, thus favouring NRF2 translocation into the nucleus. Furthermore, preliminary data revealed very low levels of the negative regulator Fyn in Ataxia Telangiectasia cells, which might account for the prolonged NRF2-activated gene expression.

Introduction

Ataxia Telangiectasia (AT) is a rare, incurable, neurodegenerative disease caused by biallelic mutations in the ATM gene [1, 2], which code for ATM, a protein of the PI3K family [3]. The lack of this single kinase leads to a highly pleiotropic phenotype [4–8]. The pathophysiological
process that underlies the disease is not completely understood, but emerging evidence suggests that oxidative stress plays a crucial role [9–13]. In the last few years, steroids have been studied extensively because they have been shown to attenuate the neurological symptoms of the disease [14–20]. Indeed, experimental studies have been conducted to identify the molecular mechanism(s) underlying their efficacy [21–28].

In our laboratory, we have discovered a new ATM transcript induced by Dexamethasone (DEX). This transcript can prompt the translation of a short ATM variant with residual kinase activity, suggesting that drug treatment can provide some gain of functions by directly replacing the kinase that is lacking [22, 28]. In addition, we have identified several pathways, enhanced by DEX at least at the transcriptional level, which can work together with the “miniATM” isoform to activate different cellular responses and partially compensate for full ATM functions [24, 27]. Recently, we have observed that DEX is able to significantly increase the levels of the endogenous antioxidants GSH and NADPH [25]. With respect to the molecular mechanisms, we have found that most of the antioxidant enzymes involved in GSH homeostasis and NADPH production are upregulated. Interestingly, we considered that the expression of all these enzymes could be under the control of NRF2, the master regulator of the antioxidant response [29]. To prove this hypothesis we showed that DEX promotes the nuclear shift of NRF2, thus activating the transcription of these antioxidant genes and, ultimately, improving the redox state of AT cells [25]. To the best of our knowledge, this was the first investigation suggesting that a glucocorticoid analogue could act as an NRF2 inducer. Due to the novelty of the finding, the mechanism of NRF2 activation by DEX is still unknown. On the other hand, there is growing interest in NRF2 as a therapeutic target in the treatment of neurodegenerative diseases [30, 31]. Thus, unravelling the molecular mechanism(s) of DEX-induced NRF2 activation in AT cells could provide new insights into the role of glucocorticoids in AT and other neurodegenerative diseases.

Hence, the aim of the present investigation was to determine how DEX exerts its effect on the NRF2-ARE system, focusing on the main pathways that are known to be involved in NRF2 activation. First, we investigated the effect of DEX on the PI3K/AKT and ERK1/2 pathways, excluding the involvement of these activating kinases. We subsequently investigated the effects of DEX on the inhibitory kinases GSK3 and p38 MAPK, finding evidence that p38 inhibition by DEX could be involved. However, experiments with p38 inhibitors suggested that p38 inhibition may not account for full NRF2 activation. Hence, we refocused our investigation on the oxidative branch of NRF2 regulation, via the KEAP1/NRF2 axis. Surprisingly, it was found that the greatest effects of DEX could be accounted for by direct inhibition of KEAP1 at both transcriptional and post-translational levels. In short, we showed that DEX decreased both KEAP1 gene transcription and protein expression and that, interestingly, it was able to induce the shift from the reduced to the oxidized form of KEAP1, thus favouring NRF2 translocation into the nucleus.

Materials and methods

Cell lines

EBV-transformed lymphoblastoid B cell lines (LCLs) established from AT patients (ATM-/-) and healthy donors (ATM+/+) were kept in RPMI1640 medium supplemented with 2 mmol/l L-glutamine, 50 mg/ml gentamycin, and 10% fetal calf serum. The LCL AT cell lines AT28RM, AT50RM and AT129RM were already described in [25]. All cells were incubated at 37°C with 5% CO₂ and treated with 100 nM DEX for 24h prior to RNA and protein extractions. Dimethylsulfoxide (DMSO) was used as the drug vehicle and thus administered in untreated cells as a control. All the cells used in this study were established for diagnostic purposes under
informed consent and stored at the Department of Clinical and Molecular Medicine, Sapienza University of Rome. The cell lines were anonymized and made available only by a coding number, so that we had no access to the name of the patients. All the cell lines were used with the approval of the ethical committee of the Sant’Andrea Hospital.

**Quantitative Real-Time PCR**

Total RNA was extracted from LCLs treated or not treated with DEX using the RNeasyPlus mini kit (Qiagen), and cDNA was obtained by PowerScript reverse transcriptase (Clontech). Quantitative PCRs for gene expression were performed by TaqMan Gene Expression Assays using the TaqMan Gene Expression Master Mix (Life Technologies) and run on a 7500 Real-Time PCR System (Applied Biosystems). HPRT1 was used as a housekeeping gene, as specified.

**Western blotting**

Western blots were performed on WT and AT cell protein extracts, essentially as described in [25]. After 24-h treatment, cells were collected, washed, and lysed in denaturing lysis buffer for total protein extracts. For cytosolic/nuclear protein extracts, cells were subjected to hypertonic lysis to obtain the cytosolic fraction and subsequent denaturing lysis on the nuclear pellet. Protein extracts were quantified, loaded onto the SDS-PAGE, transferred onto the nitrocellulose membrane and then subjected to immunoblotting. The following antibodies from Cell Signalling Technologies were used in the immunoblottting analyses: Phospho-AKT (Ser473), AKT, Phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204), p44/42 MAPK (ERK1/2), Phospho-GSK-3α/β (Ser21/9), GSK-3α/β, Fyn, LAMIN A/C, p38 MAPK, Phospho-p38 MAPK (Thr180/Tyr182) and KEAP1. Anti-MKP1, NRF2, HPRT1 and β-ACTIN were obtained from Santa Cruz Biotechnology as reported in [25]. Imaging and quantification were performed using a ChemiDoc MP Analyzer and image lab software (Bio-rad).

**Redox western**

Protein extracts for redox western were obtained in non-reducing lysis buffer, essentially as described in [32], but on fractionated protein extracts. Cells were washed in phosphate buffer saline containing 40 mM NEM and kept on ice during the whole extraction. Lysis was obtained by hypotonic lysis buffer (10 mM HEPES, pH 7.8, 10 mM KCl, 2 mM MgCl$_2$, 0.1 mM EDTA, 0.2 mM NaF, 0.2 mM Na$_3$VO$_4$) with freshly added protease inhibitors and 40 mM NEM. The suspensions were incubated on ice for 5 min, and Nonidet P40 was added to a final concentration of 0.6%. Following centrifugation at 16000 g, the pellet (nuclei) and the supernatant (cytosol) were separated. Nuclear extracts were then obtained by mild sonication in NEM lysis buffer. Both the cytosolic and nuclear extracts were diluted in 4X Sample buffer and analysed by Western blot or Redox Western blot, as described below. Half of the sample was reduced by the addition of 200 mM DTT and loaded on 4–15% SDS-PAGE to detect reduced forms of KEAP1, while the remaining extracts were loaded on a separate 4–15% SDS-PAGE under non-reducing conditions to evaluate oxidized forms of KEAP1.

**Immunoprecipitation**

For Immunoprecipitation (IP), cytosolic and nuclear extracts were incubated with NRF2 rabbit polyclonal antibody (Santa Cruz Biotechnology), and the immune complexes were pulled-down by incubation with protein A Sepharose Fast Flow Beads (GE Healthcare). Briefly, equal amounts of cytosolic and nuclear extracts belonging to the different samples (40 micrograms
of total proteins) were first denatured with 1% SDS to disrupt association of NRF2 with specific interactors. They were then subjected to IP protocol before being electrophoresed on SDS-PAGE and transferred to nitrocellulose membranes. Immunoblotting was performed with Phospho-Tyrosine Mouse mAb (Cell Signaling Technologies) or anti-Ub mouse monoclonal antibody (Santa Cruz Biotechnology) for phosphorylation and ubiquitination status, respectively.

Statistics
Statistical analyses were performed with GraphPad Prism 5 software for Windows using the paired non-parametric Wilcoxon signed-rank test. P-values < 0.05 were considered significantly different.

Results and discussion
NRF2 could be activated by different pathways, which are summarized in Fig 1A. Moreover, we recently published, and herein confirmed, that DEX is able to strongly promote the nuclear translocation of NRF2, especially in AT cells [24], (Fig 1, panels B, C). Our initial approach to investigate the molecular pathway(s) underlying the DEX effect was to focus on three different pathways for NRF2 activation. These pathways are thoroughly reviewed in [30, 33, 34] and depicted in Fig 1A.

Effect of DEX on NRF2-activating kinases
We first investigated the "activating kinase" branch involving the AKT and ERK1/2 pathways (Fig 1A, third branch). Neither AKT nor ERK 1/2 were found to be activated after 24h treatment with DEX, thus excluding their involvement in NRF2 activation (Fig 2). Not only were ERK1/2 not activated, but we also found a significant reduction in the phosphorylation status. The de-phosphorylation observed in all cells (both wild type and AT) after DEX may be imputable to the short-term overexpression of several dual-specificity phosphatase genes (DUSP1-3-6-7-8-11-14-16-22) as reported in [24, 35]. This is in contrast with our previous report showing that AKT and ERK1/2 were partially activated by drug treatment [22]. However, it must be emphasized that this activation occurred only at longer drug exposure time (72h). Moreover, it was directly related to the induction of the "mini-ATM" protein isoform, which only occurred after 48h of DEX exposure. In any case, the findings of the present study suggest that DEX could exert its effects on the "inhibitory kinase" branch rather than via direct PI3K-activation.

Effect of DEX on NRF2-inhibitory kinases
As mentioned in the introduction, in pathological conditions, the persistence of inflammatory or oxidative statuses can lead to the chronic activation of inhibitory kinases, such as GSK3 and/or p38 MAPK, which exert a negative regulation on the transcription factor NRF2 (Fig 1A, fourth branch). Accordingly, we hypothesized that DEX could have an indirect activating effect on NRF2 by blocking one or both of these inhibitory kinases.

Effect of DEX on the GSK3 inhibitory kinase. Evidence suggests that GSK3 is able to directly (or indirectly by Fyn) phosphorylate NRF2 in specific residues, leading to NRF2 degradation in a KEAP1-independent manner, in particular via the adaptor protein β-TrCP [31, 36]. Activated GSK3 is thought to phosphorylate NRF2 at specific serine residues (i.e. Ser342 and 347), but unfortunately, no phospho-specific antibodies are yet available to investigate this phenomenon. However, GSK3 activity is in turn regulated by phosphorylation on specific serine residues. In particular, phosphorylation in Ser21-GSK3α and Ser9-GSK3β acts as a switch-
Dexamethasone inhibits KEAP1 and activates NRF2 in AT cells

A

Normal Conditions

Oxidative Conditions

Activating Kinases

Inhibitory Kinases

ROS, ELECTROPHILES

GSK3

P38

HDAC

Fyn

NRF2

NRF2

NRF2

ARE genes

B

AT28RM

DEX

- 

+ 

- 

+ 

NRF2

HPRT1

LAMIN A

CYTOSOL 

NUCLEI

C

AT28RM

CTR

DEX

Cytosolic/nuclear NRF2

0.00

0.50

1.00

1.50

2.00

2.50

CYTOSOL 

NUCLEI

May 20, 2019
off mechanism for GSK3 activity since AKT is the main kinase phosphorylating GSK3 in the said positions. Hence, we investigated GSK3 phosphorylation in our samples (Fig 3A). Our results showed that the phosphorylation status of the GSK3α and β isoforms was decreased, respectively, in one out of three and two out of three AT cell lines after drug treatment (Fig 3B and 3C), which is consistent with a further activation of the kinase rather than the expected inactivation. However, the total NRF2 protein levels, determined by immunoblotting analysis on the same experimental samples used to study the GSK3 phosphorylation status, showed a statistically significant increase in the wild-type 238RM and AT129RM cell lines, while the...
NRF2 protein levels remained unchanged in the other two AT cell lines (Fig 3D and 3E). The absence of a correlation between GSK3 activation and NRF2 degradation appears to exclude the direct involvement of this kinase in the DEX-mediated NRF2 activation pathway.

Fig 3. GSK3 is not inhibited by DEX in AT cells. The activation status of the inhibitory kinase GSK3 was investigated in WT and AT cells. A) Western blot analysis for phosphorylated GSK3-α/β and total GSK3-α/β, in WT (238RM) and AT (AT28RM, AT50RM, AT129RM) cells treated as reported in Fig 2. B),C) Quantification of p-GSK3-α/total GSK3-α and of p-GSK3-β/total GSK3-β ratio, respectively. D) Western blot analysis for total NRF2 protein levels in the four cell lines used in this study, treated as in Fig 2. β-ACTIN served as a loading control. E) Quantification of the relative amounts of NRF2 in the total cell extracts of WT and AT cells shown in D. Blots shown are representative and the histograms are the means and SEM of four independent experiments. (Wilcoxon signed rank test; *two-tailed p-values<0.05).

https://doi.org/10.1371/journal.pone.0216668.g003

NRF2 protein levels remained unchanged in the other two AT cell lines (Fig 3D and 3E). The absence of a correlation between GSK3 activation and NRF2 degradation appears to exclude the direct involvement of this kinase in the DEX-mediated NRF2 activation pathway.
Nevertheless, the increased phosphorylation of GSK3 was rather unexpected considering the above reported lack of DEX-dependent activation of AKT in the AT cell lines. In agreement with our findings, proof of concept reports a “long-term” response (12h, [37]) that results in AKT down-regulation and consequent GSK3 activation in disease conditions, including chronic inflammation and neurologic diseases [38].

**Double-sided effect of DEX on Fyn kinase.** As shown in the fourth branch of Fig 1A, GSK3 is also thought to act via Fyn tyrosine kinase. Further evidence suggests that the GSK3 inhibitory effect is exerted on the regulation of the nuclear export of NRF2 by acting as upstream activator of Fyn [33]. According to Niture et al., NRF2 activation is a multi-phase process that involves: a “pre-induction phase”, during which negative regulators are exported out of the nucleus, followed by an “induction phase”, during which NRF2 is imported into the nucleus, and a “post-induction phase”, during which the negative regulators (e.g. KEAP1, Fyn, Bach1) are recruited into the nucleus to shut down the oxidant response [33]. Taken together, these considerations led us to investigate the effect of DEX on the Fyn negative regulator.

In particular, in the post-induction phase, activation of Fyn by phosphorylation, leads to the nuclear shift of Fyn itself. Once inside the nucleus, Fyn phosphorylates the tyrosine 568 of NRF2, resulting in the detachment of the transcription factor from target genes and subsequent nuclear export [39]. As mentioned above, this is a delayed response triggered to shut down NRF2 gene transcription when redox homeostasis is achieved, and, as reported in [40], it occurs by a two-step mechanism: detachment of NRF2 from ARE-dependent genes to stop transcription followed by nuclear export of NRF2 itself, which is also mediated by KEAP1. To gain more insight into this response, we first evaluated the nuclear shift of Fyn after DEX, in both WT and AT cells, and then the phosphorylation status of NRF2 after immunoprecipitation. Regarding Fyn kinase, it is very intriguing that in the investigated AT cell lines, protein levels were very low; hence, the signal was detectable only after very long exposures. It should be noted that Fyn levels are highly variable in different cells and usually poorly expressed in lymphoid cells [41, 42]. Indeed, we found low Fyn levels in several AT cell lines, while the WT showed higher Fyn levels ([S1 Fig]). To the best of our knowledge, no correlations exist between ATM and Fyn protein expression; however, this point certainly warrants further investigation.

Fig 4A shows that, in AT cells, Fyn is only cytoplasmic, while in WT cells, where the Fyn content is much higher, a portion of protein is indeed shifted into the nucleus. This is consistent with the establishment of the above-mentioned delayed response and the shutdown of transcription in WT cells. It is noteworthy that in our previous work we observed that 24 hours after DEX treatment, while NRF2 was still nuclear in both, in WT cells it was not transcribing ARE genes, while in AT cells it was [25]. In support of this hypothesis, the phosphorylation status of immunoprecipitated NRF2 confirmed a higher rate of Tyr phosphorylation in WT cells after DEX. By contrast, in AT cells, we found a significant reduction in Tyr phosphorylation accordingly with the lack of nuclear Fyn (Fig 4C and 4D). This is consistent with the pre-induction phase in which unknown kinases phosphorylate Fyn to mediate its nuclear export and degradation [33].

However, even if the lack of Fyn recruitment in AT cells can explain the prolonged activation of NRF2 and the non-appearance of the post-induction phase, it does not account for the observed triggering of the “induction phase”. Therefore, we shifted our attention to the second inhibitory kinase, p38.

**Effect of DEX on the p38 inhibitory kinase.** The p38 subfamily of MAPKs regulates gene expression in response to various extracellular stimuli and exerts a critical role in inflammation and stress response [43]. P38 is activated by dual specificity MAP kinases that phosphorylate p38 on Thr180 and Tyr 182 [43]. Inhibition of MAPK by glucocorticoids, via induction of MAPK Phosphatase-1 (DUSP1), has been extensively documented [44, 45]. In addition,
previous investigations have shown that ATM plays a crucial role in cell proliferation by suppressing ROS-p38 MAPK signalling and \( \text{ATM}^{(-/-)} \) cells show enhanced activity of the p38 mitogen-activated protein kinase (MAPK) \[46\]. In particular, Kim and Wong reported that treatment with antioxidants or with p38 MAPK inhibitors might restore normal proliferation. Taken together, these observations suggest that DEX could act as an NRF2 inducer by disrupting the negative regulation of p38.

To verify this hypothesis we evaluated the p38 activation status in WT and AT cells with or without DEX. In agreement with the findings of Kim and Wong \[46\], we observed that, at basal conditions, p38 is indeed more activated in AT cells than it is in WT cells (Fig 5A and 5B). In addition, we found that 24-hour DEX treatment was able to reduce this activation significantly. In addition, the time-dependent inhibition of p38 by DEX in AT129RM cells clearly suggests that the greatest effect is after 24 hours (Fig 5C).
Inactivation of MAPK in mammalian cells is achieved by a family of dual-specificity MAPK phosphatases (MKP), which target the two critical phosphorylation sites in the activation loop.

**Fig 5. P38 switch-off by DEX and concomitant DUSP1 switch-on.**

A) Western blot analysis for phosphorylated p38 and total p38 in WT (238RM) and AT (AT28RM, AT50RM, AT129RM) cells treated as reported in Fig 2. β-ACTIN served as a loading control.

B) Quantification of p-p38/total p38 ratio.

C) Western blot analysis for phosphorylated p38 and total p38 in the AT129RM cell line treated with DEX for 2-6-24h or not treated.

E) Relative DUSP1 mRNA level in WT and AT cells treated as in A).

D),F) Time-course of p38 switch-off and DUSP1/MKP1 switch-on, respectively, in the AT129RM cell line treated with DEX for 2-6-24h or not treated; asterisks refer to the respective t0 value. Blots shown are representative and the histograms (B,E) are the means and SEM of four independent experiments (Wilcoxon signed rank test; *two-tailed p-values < 0.05).

https://doi.org/10.1371/journal.pone.0216668.g005
of MAPK. Among the characterized MKPs, MKP1 is known to be responsible for the de-phosphorylation and consequent inactivation of p38 [47, 48]. As reported above, it is well known that dexamethasone inhibits p38 MAPK by trans-activating the dual specificity phosphatase 1 gene (DUSP1), which codes for the corresponding MAPK phosphatase 1 (MKP1) protein [44, 45]. We therefore investigated whether p38 switch-off could be due to direct activation of MKP1, and we observed a significant transactivation of DUSP1 after DEX treatment (Fig 5E), consistent with the previously observed p38 inhibition (Fig 5B). Panels D, F and G in Fig 5 show the time-dependent inactivation of p38 accompanied by the concomitant DUSP1 mRNA induction and the corresponding MKP1 protein expression in the AT129RM cell line.

To verify whether NRF2 activation was to some extent attributable to the observed p38 inhibition by DEX, we investigated whether a p38 inhibitor could mimic the same effect of the glucocorticoid analogue on NRF2 activation, in the WT cell line and in one AT cell line as models.

To this end, we treated WT and AT129RM cells with increasing doses (50 and 100 nM) of the p38 inhibitor, SB202190. SB202190, which does not affect other MAKPs (i.e. JNK, ERK1/2, etc.), is a highly selective potent inhibitor of all p38 isoforms, with an IC50 of 50–100 nM [49]. In parallel, we administered the DEX treatment. In Fig 6A and 6B we can observe how DEX was able to significantly inactivate p38 only in the AT cell line, and this occurred in an MKP1-dependent manner, as supported by the concomitant DUSP1 mRNA induction (Fig 6C), while the SB202190 inhibitor was not effective in significantly lowering p-p38 levels in either cell model. Nevertheless, the SB202190 inhibitor acts in a different way than DEX (it binds to the active protein lowering its affinity for the ATP substrate, thus not affecting the phosphorylation status of the protein). We therefore used a different approach to demonstrate effective p38 inhibition. Considering that active p38 is able to favour the stability of some pro-inflammatory transcripts (such as IL-23p19) [50], we assessed whether SB202190 was indeed able to affect p38 activity by determining the IL-23p19 mRNA levels in our experimental conditions. Fig 6D shows that the inhibitor actually decreased the levels of the IL-23p19 transcript in a dose-dependent manner. After having verified the efficacy of both drugs in inhibiting p38, we compared the expression of a selected NRF2 target gene used as a control for transcription factor activation. We found that DEX was able to significantly increase the glutamate-cysteine ligase catalytic subunit (GCLC) mRNA, whereas SB202190 was not (Fig 6E).

In light of these results, we turned our attention to the nuclear shift of NRF2 demonstrated in [25] and repeated the experiments in the presence of the p38 inhibitor. We found that, after SB202190 treatment, NRF2 nuclear levels in AT cells are clearly lower than those of cells treated with DEX (Fig 6F and 6G); this is consistent with the low (not significant) induction of model target genes (Fig 6E). Taken together, these results led us to rule out the contribution of p38 in NRF2 activation after DEX treatment. We therefore refocused our attention on the first branch of our outline in Fig 1A, which addresses the nuclear-cytoplasmic shuttling of NRF2 under oxidative conditions.

### Effect of DEX on KEAP1 and the oxidative pathway

One of the most studied mechanisms of activation of NRF2 are the redox stressors, which put the Kelch-like ECH-associated protein 1 (KEAP1) out of play. KEAP1 is an NRF2 repressor that is inactivated by stress-stimulated modification of thiols elicited by oxidants and/or electrophiles [34]. Modifications of Cys residues in KEAP1 block cullin-3 ring ubiquitin ligase complex activity allowing newly synthesized NRF2 to accumulate and move to the nucleus (Fig 1A and 1B). KEAP1 is a relatively cysteine-rich protein that is mainly located in the cytosol as a dimer targeting NRF2 to proteasome degradation [51].
Dexamethasone inhibits KEAP1 and activates NRF2 in AT cells

A

|          | 238RM | AT129RM |
|----------|-------|---------|
| DEX      |       |         |
| SB202190 | 0     | 0       |
|          | 50    | 0       |
|          | 100   | +       |

- p-p38
- p38
- β-ACTIN

B

| SB202190 |       |         |
|----------|-------|---------|
| 0 nM     |       |         |
| 50 nM    |       |         |
| 100 nM   |       |         |
| DEX 100 nM |     |         |

- P-p38/p38

C

| SB202190 |       |         |
|----------|-------|---------|
| 0 nM     |       |         |
| 50 nM    |       |         |
| 100 nM   |       |         |
| DEX 100 nM |     |         |

- Relative DUSP1 mRNA levels

D

| SB202190 |       |         |
|----------|-------|---------|
| 0 nM     |       |         |
| 50 nM    |       |         |
| 100 nM   |       |         |
| DEX 100 nM |     |         |

- Relative IL-23p19 mRNA levels

E

| SB202190 |       |         |
|----------|-------|---------|
| 0 nM     |       |         |
| 50 nM    |       |         |
| 100 nM   |       |         |
| DEX 100 nM |     |         |

- Relative GCLC mRNA levels

F

| SB202190 |       |         |
|----------|-------|---------|
| 0 nM     |       |         |
| 50 nM    |       |         |
| 100 nM   |       |         |
| DEX 100 nM |     |         |

- NRF2
- LAMIN A
- HPRT1

G

| SB202190 |       |         |
|----------|-------|---------|
| 0 nM     |       |         |
| 50 nM    |       |         |
| 100 nM   |       |         |
| DEX 100 nM |     |         |

- Relative NRF2 nuclear levels
KEAP1 cytosolic-nuclear shuttling. As we can observe in Fig 7A, under resting conditions, KEAP1 is mainly cytosolic in both WT and AT129RM cells, as we would expect. However, after DEX treatment, we found a significant reduction in cytosolic KEAP1 in AT cells, which is not compensated for by a comparable increase in the nuclear fraction (Fig 7B). Thus, we hypothesised that DEX could directly affect KEAP1 protein expression.

KEAP1 mRNA and protein expression. Indeed, we found a net decrease in the KEAP1 protein after DEX treatment, but only in AT cells (Fig 7C and 7D). To confirm our hypothesis, we tested whether the decreased protein level was paralleled by a downregulation of KEAP1 gene expression, and we found that KEAP1 mRNA was indeed significantly reduced after DEX treatment, only in AT cells (Fig 7E). The mRNA and protein expression levels were tested also in the other AT cell lines, confirming the downregulation (S2 Fig). This finding stands in contrast with what has been reported in the literature, according to which, the KEAP1 gene is up regulated by NRF2 itself as a negative feedback mechanism [52]. Nevertheless, considering that the marked effect was observed at the protein level, we wondered whether this reduction was also due to protein oxidation and subsequent degradation.

Redox Western KEAP1. Highly reactive cysteine residues, within the domains of KEAP1, set up at least three different redox sensor systems. Cys151 is crucial for oxidation by tBHQ and sulphoraphane, and can form a transient disulphide bridge with Cys151 in another KEAP1 subunit [32]; Cys273 and 288 recognize alkenals and prostaglandins [32, 53–55], while Cys226 and 613 recognize metals and form transient intramolecular disulphide bridge [32, 53]. Hence, as a final line of inquiry, we sought to determine whether DEX was able to affect the oxidation status of KEAP1 by redox western blot as reported in [32]. Hence, we performed electrophoretic runs on the same cytosolic/nuclear extracts under both non-reducing and reducing SDS-PAGE. Our results in Fig 7F show that oxidized forms of KEAP1 (namely Ox1 and Ox2) are indeed detectable in non-reducing SDS-PAGE. These two higher isofoms are supposed to be formed by an intermolecular disulphide bridge between the cysteine residues of two KEAP1 molecules (homodimer) or KEAP1 together with another protein (heterodimer) [32]. However, as reported by Fouquet et al., in both cases, KEAP1 homo/hetero-dimer is no longer able to interact with NRF2 to keep it in the cytosol. In particular, their model suggests that the stress signal and/or electrophiles disrupt the KEAP1-Cul3 axis by modifying the Cys151 residue on KEAP1, thus stopping the inhibitory effect and leading to NRF2 release. Quantifying the Ox1 bands in our blots (Fig 7G), we found an increase in WT and especially in AT cells after DEX treatment, which is consistent with a further inactivation of KEAP1 and consequent activation of NRF2. To directly prove that KEAP1 is indeed responsible for modulating NRF2 after DEX treatment, we investigated whether the increase in the oxidized form of KEAP1 corresponds to alterations in NRF2 ubiquitination levels. To this end, NRF2 protein was immunoprecipitated from both cytosolic and nuclear extracts and then immunoblotted with anti-ubiquitin antibody. The results obtained show that NRF2 ubiquitination status was indeed decreased after DEX, which is consistent with the increased oxidation of KEAP1 (Fig 7H and 7I). To the best of our knowledge, this is the first report addressing the effect of DEX...
Dexamethasone inhibits KEAP1 and activates NRF2 in AT cells.

**Figure A**

KEAP1, LAMIN A, and HPRT1 levels in cytosol and nuclei of 238RM and AT129RM cells treated with DEX.

**Figure B**

Bar graphs showing the cytosolic/nuclear KEAP1 levels for 238RM and AT129RM cells treated with control (CTR) or DEX.

**Figure C**

KEAP1 and β-ACTIN levels in 238RM and AT129RM cells treated with DEX.

**Figure D**

Relative KEAP1 protein levels for 238RM and AT129RM cells treated with control (CTR) or DEX.

**Figure E**

Relative KEAP1 mRNA levels for 238RM and AT129RM cells treated with control (CTR) or DEX.

**Figure F**

KEAP1, LAMIN A, and HPRT1 levels in cytosol and nuclei of 238RM and AT129RM cells treated with DEX.

**Figure G**

Relative KEAP1 levels for 238RM and AT129RM cells treated with control (CTR) or DEX.

**Figure H**

Western blots for Ub, NRF2, LAMIN A, and HPRT1 in cytosol and nuclei of 238RM and AT129RM cells treated with DEX.

**Figure I**

Ub/NRF2 levels for WT, 238RM, and AT129RM cells treated with control (CTR) or DEX.
as an NRF2 inducer that acts by disrupting the NRF2-KEAP1 complex. Other authors [56–58] have described a similar effect, but it must be emphasized that they used a Dexamethasone that was modified with a mesylate group, which is responsible for the oxidative properties.

Conclusions

In conclusion, in the present investigation we have shown that in AT cells, the activation of NRF2 by the glucocorticoid analogue DEX does not occur via activating or inactivating kinases, as commonly described in the literature. In fact, neither AKT nor ERK1/2 activating kinases were activated and GSK3 inactivating kinase was not inhibited, thus excluding their involvement in NRF2 activation. Regarding the effect of DEX on the p38 MAPK inactivating kinase, despite a significant p38 inhibition, this effect does not seem to have a role in NRF2 activation or stabilization. Our results suggest that the effect of DEX is more likely exerted directly on the KEAP1 inhibitory protein and that this effect involves the oxidative pathway.

As we have shown, both KEAP1 mRNA and protein levels are reduced after drug treatment. In addition, an increase in oxidized and inactive forms of KEAP1, which corresponds to a decrease in NRF2 ubiquitination status, was observed. This result is consistent with a recent study describing the transcriptomic and proteomic profile of AT cells treated with DEX. The study described the upregulation of several proteins involved in protein metabolism and processing in the endoplasmic reticulum, protein folding and post-translational modifications [27]. Together, our findings suggest that NRF2 induction upon treatment with DEX is not mediated by p38, but rather, by KEAP1 inhibition and that is sustained by a delay in the post-induction phase, via Fyn kinase, which keeps NRF2 active in the nucleus. However, further investigations are necessary to gain a better understanding of the long-term effects of DEX in this phase and in particular, the regulation of Fyn expression in AT cells.

Supporting information

S1 Fig. Fyn protein expression in WT and AT cell lines. A),B) Western blot analysis for Fyn in the total extracts of WT (238RM) and AT (AT28RM, AT50RM, AT129RM) cells treated with DEX or not treated, as indicated. β-ACTIN served as a loading control. C), D) Quantification of the relative amount of Fyn protein in the total cell extracts of WT and AT cell lines tested in A and B. Blots shown are representative and the histograms are the means and SEM of three independent experiments.

S2 Fig. KEAP1 mRNA and protein expression in AT cell lines. A) KEAP1 mRNA level in AT28RM and AT50RM cells treated with DEX or not treated, as indicated. HPRT1 was used as the housekeeping gene for data normalization. B) Western blot analysis for KEAP1 in the total extracts derived from the same cell lines analysed in A. β-ACTIN served as a loading control.
control. C) Quantification of the relative amount of KEAP1 protein in the total cell extracts of AT cell lines tested in B. Blots shown are representative and the histograms are the means and SEM of four independent experiments (Wilcoxon signed rank test; * two-tailed p-values < 0.05).

Author Contributions

Conceptualization: Sara Biagiotti.
Data curation: Sara Biagiotti.
Formal analysis: Sara Biagiotti.
Investigation: Sara Biagiotti.
Methodology: Sara Biagiotti.
Project administration: Mauro Magnani.
Resources: Mauro Magnani.
Supervision: Marzia Bianchi, Luigia Rossi, Luciana Chessa.
Writing – original draft: Sara Biagiotti, Marzia Bianchi.
Writing – review & editing: Sara Biagiotti, Marzia Bianchi, Luigia Rossi, Luciana Chessa, Mauro Magnani.

References

1. Boder E, Sedgwick RP. Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, ocularcutaneous telangiectasia and frequent pulmonary infection. Pediatrics. 1958; 21(4):526–54. PMID: 13542097
2. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995; 268(5218):1749–53. https://doi.org/10.1126/science.7792600 PMID: 7792600
3. Brown KD, Ziv Y, Sadanandan SN, Chessa L, Collins FS, Shiloh Y et al. The ataxia-telangiectasia gene product, a constitutively expressed nuclear protein that is not up-regulated following genome damage. Proceedings of the National Academy of Sciences of the United States of America. 1997; 94(5):1840–5. https://doi.org/10.1073/pnas.94.5.1840 PMID: 9050866
4. Ambrose M, Gatti RA. Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. Blood. 2013; 121(20):4036–45. https://doi.org/10.1182/blood-2012-09-456897 PMID: 23440242
5. Barlow C, Denney PA, Shigenaga MK, Smith MA, Morrow JD, Roberts LJ et al. Loss of the ataxia-telangiectasia gene product causes oxidative damage in target organs. ProcNatlAcadSciUSA . 1999; 96 (17):9915–9. PMC22310.
6. Biton S, Barzilai A, Shiloh Y. The neurological phenotype of ataxia-telangiectasia: solving a persistent puzzle. DNA Repair (Amst). 2008; 7(7):1028–38. https://doi.org/10.1016/j.dnarep.2008.03.006 PMID: 18456574
7. Chun HH, Gatti RA. Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst). 2004; 3(8–9):1187–96. https://doi.org/10.1016/j.dnarep.2004.04.010 PMID: 15279807
8. Gilad S, Chessa L, Khosravi R, Russell P, Galanty Y, Plane M et al. Genotype-phenotype relationships in ataxia-telangiectasia and variants. American journal of human genetics. 1998; 62(3):551–61. https://doi.org/10.1086/301755 PMID: 9497252
9. Barzilai A, Rotman G, Shiloh Y. ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. DNA Repair (Amst). 2002; 1(1):3–25. https://doi.org/10.1016/S1568-7864(01)00007-6.
10. Kamsler A, Daily D, Hochman A, Stern N, Shiloh Y, Rotman G et al. Increased oxidative stress in ataxia telangiectasia evidenced by alterations in redox state of brains from Atm-deficient mice. Cancer research. 2001; 61(5):1849–54. PMC11280737. PMID: 11280737
Dexamethasone inhibits KEAP1 and activates NRF2 in AT cells

11. Pauli TT. Mechanisms of ATM Activation. Annual review of biochemistry. 2015; 84:711–38. https://doi.org/10.1146/annurev-biochem-060614-034335 PMID: 25580527

12. Reichenbach J, Schubert R, Schindler D, Muller K, Bohles H, Zielen S. Elevated oxidative stress in patients with ataxia telangiectasia. Antioxidants & redox signaling. 2002; 4(3):465–9. https://doi.org/10.1089/15230860209162654 PMID: 12215213

13. Rotman G, Shiloh Y. Ataxia-telangiectasia: is ATM a sensor of oxidative damage and stress? BioEssays: news and reviews in molecular, cellular and developmental biology. 1997; 19(10):911–7. https://doi.org/10.1002/bies.950191011 PMID: 9363685

14. Giardino G, Fusco A, Romano R, Gallo V, Maio F, Esposito T et al. Betamethasone therapy in ataxia telangiectasia. Archives of neurology. 2006; 63(10):1479–82. https://doi.org/10.1001/archneur.63.10.1479 PMID: 17030666

15. Broccoletti T, Del Giudice E, Amorosi S, Russo I, Di Bonito M, Imperati F et al. Steroid-induced improvement of neurological signs in ataxia-telangiectasia patients. European journal of neurology. 2008; 15 (3):223–8. https://doi.org/10.1111/j.1468-1331.2008.02060.x PMID: 18290844

16. Gatti RA, Perlman S. A proposed bailout for A-T patients? European journal of neurology. 2009; 16 (6):653–5. https://doi.org/10.1111/j.1468-1331.2009.02597.x PMID: 19459929

17. Broccoletti T, Del Giudice E, Cirillo E, Vigliano I, Giardino G, Ginocchio VM et al. Efficacy of very-low-dose betamethasone on neurological symptoms in ataxia-telangiectasia. European journal of neurology. 2011; 18(4):564–70. https://doi.org/10.1111/j.1468-1331.2010.03203.x PMID: 20840352

18. Quarantelli M, Giardino G, Prinster A, Aloj G, Carotenuto B, Cirillo E et al. Steroid treatment in Ataxia-Telangiectasia induces alterations of functional magnetic resonance imaging during prono-supination task. European journal of paediatric neurology: EJPN: official journal of the European Paediatric Neurology Society. 2013; 17(2):135–40. https://doi.org/10.1016/j.ejpn.2012.06.002 PMID: 22763152

19. Chessa L, Leuzzi V, Plebani A, Soresina A, Michel R, D’Agnano D et al. Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia telangiectasia patients: results of a phase 2 trial. Orphanet journal of rare diseases. 2014; 9:5. https://doi.org/10.1186/1750-1172-9-5 PMID: 24405665

20. Leuzzi V, Michel R, D’Agnano D, Molinaro A, Venturi T, Plebani A et al. Positive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia. Neurology(R) neuroimmunology & neuroinflammation. 2015; 2(3):e98. https://doi.org/10.1212/NXI.0000000000000098 PMID: 25884015

21. Russo I, Cosentino C, Del Giudice E, Broccoletti T, Amorosi S, Cirillo E et al. In ataxia-telangiectasia betamethasone response is inversely correlated to cerebellar atrophy and directly to antioxidative capacity. European journal of neurology. 2009; 16(6):755–9. PMC19475758. PMID: 19475758

22. Menotta M, Biagiotti S, Bianchi M, Chessa L, Magnani M. Dexamethasone partially rescues ataxia telangiectasia-mutated (ATM) deficiency in ataxia telangiectasia by promoting a shortened protein variant retaining kinase activity. The Journal of biological chemistry. 2012; 287(49):41352–63. https://doi.org/10.1074/jbc.M112.344473 PMID: 23095520

23. Giardino G, Fusco A, Romano R, Gallo V, Maio F, Esposito T et al. Betamethasone therapy in ataxia telangiectasia: unraveling the rationale of this serendipitous observation on the basis of the pathogenesis. European journal of neurology. 2013; 20(5):740–7. https://doi.org/10.1111/ene.12024 PMID: 23213281

24. Biagiotti S, Menotta M, Giacomini E, Radici L, Bianchi M, Bozzao C et al. Forward subtractive libraries containing genes transactivated by dexamethasone in ataxia telangiectasia lymphoblastoid cells. Molecular and cellular biochemistry. 2014; 392(1–2):13–30. https://doi.org/10.1007/s11100-014-2013-7 PMID: 244110244

25. Biagiotti S, Menotta M, Orazi S, Spapperi C, Brundu S, Fraternelle A et al. Dexamethasone improves redox state in ataxia telangiectasia cells by promoting an NRF2-mediated antioxidant response. FEBS J. 2016; 283(21):3962–78. https://doi.org/10.1111/febs.13901 PMID: 27636996

26. Menotta M, Biagiotti S, Bartolini G, Marzia B, Orazi S, Germani A et al. Nano-Mechanical Characterization of Ataxia Telangiectasia Cells Treated with Dexamethasone. Cell BiochemBiophysics. 2017; 75 (1):95–102. https://doi.org/10.1007/s10529-016-0775-0 [pii]. PMID: 27933465

27. Menotta M, Biagiotti S, Orazi S, Rossi L, Chessa L, Leuzzi V et al. In vivo effects of dexamethasone on blood gene expression in ataxia telangiectasia. MolCell Biochem. 2018; 438(1–2):153–66. https://doi.org/10.1007/s11010-017-3122-x [pii]. PMID: 28744512

28. Menotta M, Biagiotti S, Spapperi C, Orazi S, Rossi L, Chessa L et al. ATM splicing variants as biomarkers for low dose dexamethasone treatment of A-T. OrphanetJ RareDis. 2017; 12(1):126. https://doi.org/10.1186/s13023-017-0669-2 [pii]. PMID: 28879388

29. Giardino G, Fusco A, Romano R, Gallo V, Maio F, Esposito T et al. Betamethasone therapy in ataxia telangiectasia: unraveling the rationale of this serendipitous observation on the basis of the pathogenesis. European journal of neurology. 2013; 20(5):740–7. https://doi.org/10.1111/ene.12024 PMID: 23213281
30. Buendia I, Michalska P, Navarro E, Gameiro I, Egea J, Leon R. Nrf2-ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases. PharmacolTher. 2016; 157:84–104. S0163-7258(15)00216-8 [pii]; https://doi.org/10.1016/j.pharmthera.2015.11.003 PMID: 26617217

31. Esteras N, Dinkova-Kostova AT, Abramov AY. Nrf2 activation in the treatment of neurodegenerative diseases: a focus on its role in mitochondrial bioenergetics and function. BioChem. 2016; 397(5):383–400. https://doi.org/10.1515/hz-2015-0295 [pii]; https://bchm.just Accepted-hz-2015-0295/hz-2015-0295.xml [pii]. PMID: 26812787

32. Fourquet S, Guerouis R, Biard D, Toledano MB. Activation of Nrf2 by nitrosative agents and H2O2 involves KEAP1 disulfide formation. J BiolChem. 2010; 285(11):8463–71. M109.051714 [pii]; https://doi.org/10.1074/jbc.M109.051714 PMID: 20061377

33. Niture SK, Khatri R, Jaiswal AK. Regulation of Nrf2-an update. Free RadicBiolMed. 2014; 66:36–44. S0891-5849(13)00661-0 [pii]; https://doi.org/10.1016/j.freeradbiomed.2013.02.008 PMID: 23434765

34. Fourquet S, Guerouis R, Biard D, Toledano MB. Activation of Nrf2 by nitrosative agents and H2O2 involves KEAP1 disulfide formation. J BiolChem. 2010; 285(11):8463–71. M109.051714 [pii]; https://doi.org/10.1074/jbc.M109.051714 PMID: 20061377

35. Niture SK, Khatri R, Jaiswal AK. Regulation of Nrf2-an update. Free RadicBiolMed. 2014; 66:36–44. S0891-5849(13)00661-0 [pii]; https://doi.org/10.1016/j.freeradbiomed.2013.02.008 PMID: 23434765

36. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002; 298(5600):1911–2. https://doi.org/10.1126/science.1072682 PMID: 12213902

37. Martin D, Salinas M, Fujita N, Tsuruo T, Cuadrado A. Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/beta-TrCP axis. MolCell Biol. 2012; 32(17):3486–99. MCB.00180-12 [pii]; https://doi.org/10.1128/MCB.00180-12 PMID: 22751928

38. Martin D, Salinas M, Fujita N, Tsuruo T, Cuadrado A. Ceramide and reactive oxygen species generated by H2O2 induce caspase-3-independent degradation of Akt/protein kinase B. J BiolChem. 2002; 277(45):42843–52. https://doi.org/10.1074/jbc.M201070200 PMID: 12213902

39. Jain AK, Jaiswal AK. GSX-3beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. J BiolChem. 2007; 282(22):16502–10. M611336200 [pii]; https://doi.org/10.1074/jbc.M611336200 PMID: 17403689

40. Anuranjani, Bala M. Concerted action of Nrf2-ARE pathway, MRN complex, HMGB1 and inflammatory cytokines—implication in modification of radiation damage. RedoxBiol. 2014; 2:832–46. https://doi.org/10.1016/j.redox.2014.02.008 S2213-2317(14)00047-0 [pii]. PMID: 25009785

41. Cooke MP, Perlmutter RM. Expression of a novel form of the fyn proto-oncogene in hematopoietic cells. The New biologist. 1989; 1(1):66–74. PMC2488273. PMID: 2488273

42. Weil R, Levraud JP, Dodon MD, Bessia C, Hazan U, Kourilsky P et al. Altered expression of tyrosine kinases of the Src and Syk families in human T-cell leukemia virus type 1-infected T-cell lines. Journal of virology. 1999; 73(5):3709–17. PMID: 10196263.

43. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002; 298(5600):1911–2. https://doi.org/10.1126/science.1072682 PMID: 12471242

44. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. The New England journal of medicine. 2005; 353(16):1711–23. https://doi.org/10.1056/NEJMra050541 PMID: 16236742

45. Barnes PJ. Glucocorticosteroids: current and future directions. British journal of pharmacology. 2011; 163(1):29–43. https://doi.org/10.1111/j.1476-5381.2010.01199.x PMID: 21198556

46. Kim J, Wong PK. Loss of ATM impairs proliferation of neural stem cells through oxidative stress-mediated p38 MAPK signaling. Stem cells. 2009; 27(8):1987–98. https://doi.org/10.1002/stem.125 PMID: 19544430

47. Chen P, Hutter D, Yang X, Gorospe M, Davis RJ, Liu Y. Discordance between the binding affinity of mitogen-activated protein kinase subfamily members for MAP kinase phosphatase-2 and their ability to activate the phosphatase catalytically. The Journal of biological chemistry. 2001; 276(31):29440–9. https://doi.org/10.1074/jbc.M103463300 PMID: 11387537

48. Kiemer AK, Weber NC, Furst R, Bildner N, Kulhanek-Heinze S, Vollmar AM. Inhibition of p38 MAPK activation via induction of MKP-1: atrial natriuretic peptide reduces TNF-alpha-induced actin polymerization and endothelial permeability. Circulation research. 2002; 90(8):874–81. https://doi.org/10.1161/01.RES.0000017068.58856.F3 PMID: 11988488
49. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. The Biochemical journal. 2000; 351(1Pt 1):95–105. https://doi.org/10.1042/0264-6021:351 0095 PMID: 10998351.

50. Palma L, Sfara C, Antonelli A, Magnani M. Dexamethasone restrains ongoing expression of interleukin-23p19 in peripheral blood-derived human macrophages. BMC pharmacology. 2011; 11:8. https://doi.org/10.1186/1471-2210-11-8 PMID: 21791059

51. Itoh K, Wakabayashi N, Katoh Y, Ishii T, O’Connor T, Yamamoto M. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes to cells: devoted to molecular & cellular mechanisms. 2003; 8(4):379–91. https://doi.org/10.1046/j.1365-2443.2003.00640.x

52. Chorley BN, Campbell MR, Wang X, Karaca M, Sambandan D, Bangura F et al. Identification of novel Nrf2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha. Nucleic acids research. 2012; 40(15):7416–29. https://doi.org/10.1093/nar/gks409 PMID: 22581777

53. McMahon M, Lamont DJ, Beattie KA, Hayes JD. Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(44):18838–43. https://doi.org/10.1073/pnas.1007387107 PMID: 20956331

54. Kobayashi M, Li L, Iwamoto N, Nakajima-Takagi Y, Kaneko H, Nakayama Y et al. The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds. Molecular and cellular biology. 2009; 29(2):493–502. https://doi.org/10.1128/MCB.01080-08 PMID: 19001094

55. Yamamoto T, Suzuki T, Kobayashi A, Wakabayashi J, Maher J, Motohashi H et al. Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Molecular and cellular biology. 2008; 28(8):2758–70. https://doi.org/10.1128/MCB.01704-07 PMID: 18268004

56. Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y et al. Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci USA. 2002; 99(18):11908–13. https://doi.org/10.1073/pnas.172398899 172398899 [pii]. PMID: 12193649

57. Saito R, Suzuki T, Hiramoto K, Asami S, Naganuma E, Suda H et al. Characterizations of Three Major Cysteine Sensors of Keap1 in Stress Response. Molecular and cellular biology. 2016; 36(2):271–84. https://doi.org/10.1128/MCB.00868-15 PMID: 26527616

58. Copple IM, Goldring CE, Jenkins RE, Chia AJ, Randle LE, Hayes JD et al. The hepatotoxic metabolite of acetaminophen directly activates the Keap1-Nrf2 cell defense system. Hepatology. 2008; 48(4):1292–301. https://doi.org/10.1002/hep.22472 PMID: 18795192